| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44010413 | HTLV-1 | ENSG00000143322.22 | protein_coding | ABL2 | Yes | No | 27 | P42684 |
| TVIS44018574 | HTLV-1 | ENSG00000143322.22 | protein_coding | ABL2 | Yes | No | 27 | P42684 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ABL2 |
|---|---|
| DrugBank ID | DB01254 |
| Drug Name | Dasatinib |
| Target ID | BE0000435 |
| UniProt ID | P42684 |
| Regulation Type | multitarget |
| PubMed IDs | 20072833; 17684099 |
| Citations | Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7.@@Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G: The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. Epub 2007 Aug 7. |
| Groups | Approved; Investigational |
| Direct Classification | Aromatic anilides |
| SMILES | CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1 |
| Pathways | Dasatinib Inhibition of BCR-ABL |
| PharmGKB | PA162372878 |
| ChEMBL | CHEMBL1421 |
